Pharmaceutical - Pharmaceutical, Bayer

Filter

Current filters:

PharmaceuticalBayer

Popular Filters

1 to 25 of 293 results

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

02-09-2014

German pharma and chemical major Bayer has released results from the X-VeRT* study, demonstrating that…

BayerCardio-vascularPharmaceuticalResearchXarelto

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

11-08-2014

The treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through…

BayerGleevecGlivecMarkets & MarketingNovartisOncologyPfizerPharmaceuticalStivargaSutent

Eylea approved for diabetic macular edema in Europe

Eylea approved for diabetic macular edema in Europe

11-08-2014

The European Commission has approved German pharma major Bayer’s Eylea (aflibercept) injection for…

BayerEuropeEyleaOphthalmicsOphthalmologyPharmaceuticalRegeneronRegulation

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

30-07-2014

Germany’s pharma and life sciences major Bayer posted a solid set of second-quarter 2014 financial…

BayerCancerConsumer HealthFinancialGermanyGermanyPharmaceuticalPulmonary hypertension

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

Bayer and Onyx report disappointing Phase III results of Nexavar in breast cancer

25-07-2014

German drug major Bayer and Onyx Pharmaceuticals, an Amgen subsidiary (Nasdaq: AMGN), have said that…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Bayer the latest in anticoagulant lawsuit action

Bayer the latest in anticoagulant lawsuit action

16-07-2014

German drug major Bayer is just one of the latest companies to be facing lawsuits over its anticoagulants,…

BayerBoehringer IngelheimHematologyHematologyLegalPharmaceuticalPradaxaRivaroxabanUSAWarfarin SodiumXarelto

Malini Moorthy joins Bayer as head of litigation

Malini Moorthy joins Bayer as head of litigation

16-07-2014

Bayer Corporation, a US subsidiary of German drug major Bayer has hired Malini Moorthy as head of its…

BayerBayer CorporationBoardroomEconomy of GermanyGermanyHead of the litigation departmentIG FarbenMalini MoorthyPharmaceuticalUSA

Bayer milestone for Compugen in cancer immunotherapy deal

Bayer milestone for Compugen in cancer immunotherapy deal

07-07-2014

Shares of Israel-based Compugen rose nearly 4% in pre-market trading today, after it said it has achieved…

BayerCompugenFinancialOncologyPharmaceuticalResearch

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP

27-06-2014

Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

20-06-2014

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved German pharma major Bayer’s oral…

BayerJapanNexavarOncologyPharmaceuticalRegulation

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

11-06-2014

German pharma major Bayer has submitted an application to the European Medicines Agency seeking marketing…

BayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulation

Dieter Weinand to become president of Bayer HealthCare

Dieter Weinand to become president of Bayer HealthCare

05-06-2014

Dieter Weinand will become President of the HealthCare division of German pharma major Bayer Pharmaceuticals,…

BayerBoardroomPharmaceuticalUSA

Planned top executive moves at Bayer and Sanofi

04-06-2014

There were a couple of surprise planned departures and relocations revealed at European pharmaceutical…

BayerBoardroomManagementPharmaceuticalSanofi

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

Bayer pays upfront $50 million for Orion’s prostate cancer candidate ODM-201

02-06-2014

Finland-based drugmaker Orion Corp has entered into a global partnership with German pharma major Bayer…

BayerGlobalLicensingODM-201OncologyOrion CorpPharmaceuticalResearch

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Bayer explores Russian options in the context of Pharma 2020 strategy

Bayer explores Russian options in the context of Pharma 2020 strategy

28-05-2014

Bayer HealthCare, one of the business units of German drug major Bayer, is exploring all options for…

Abbott LaboratoriesBayerGermanyHealthcareManufacturing plantOzonPharmaceuticalPharmaceutical drugPharmacologyPoliticsRussia

Bayer divests interventional device business for $415 million

15-05-2014

German pharma and life sciences major Bayer has entered into a definitive agreement to sell its interventional…

BayerMergers & AcquisitionsPharmaceutical

Bayer to make clinical trial data more accessible to researchers

Bayer to make clinical trial data more accessible to researchers

14-05-2014

German drug major Bayer has joined a host of other pharma companies in announcing that it will start…

BayerBoehringer IngelheimGermanyHealth Medical PharmaPharmaceuticalPharmaceutical industryPharmaceutical sciencesResearchScience

FDA approves new indication for Bayer's Kogenate

12-05-2014

The US Food and Drug Administration has approved a new indication for German drug major Bayer's Kogenate…

BayerHematologyKogenate FSPharmaceuticalRegulationUSA

1 to 25 of 293 results

Back to top